| Document and Entity Information - shares | 9 Months Ended | |
| Sep. 30, 2016 | Apr. 17, 2017 | |
| Document and Entity Information: | ||
| Entity Registrant Name | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. | |
| Document Type | 10-Q | |
| Document Period End Date | Sep. 30, 2016 | |
| Trading Symbol | tsoi | |
| Amendment Flag | false | |
| Entity Central Index Key | 1,419,051 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Common Stock, Shares Outstanding | 765,251,000 | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Current Reporting Status | Yes | |
| Entity Voluntary Filers | No | |
| Entity Well-known Seasoned Issuer | No | |
| Document Fiscal Year Focus | 2,016 | |
| Document Fiscal Period Focus | Q3 |
| Unaudited Condensed Consolidated Balance Sheets - USD ($) | Sep. 30, 2016 | Dec. 31, 2015 |
| Current assets: | ||
| Cash and cash equivalents | $ 45,233 | $ 2,183 |
| Accounts Receivable, net | 0 | 2,184 |
| Inventories | 38,351 | 29,675 |
| Prepaid expenses and other current assets | 13,287 | 213,446 |
| Total current assets | 96,871 | 247,488 |
| Other assets | 28,844 | 12,476 |
| Total assets | 125,715 | 259,964 |
| Current liabilities: | ||
| Accounts payable | 321,691 | 277,342 |
| Accrued expenses and other current liabilities | 91,430 | 17,986 |
| Notes payable-related parties | 198,669 | 193,664 |
| Total current liabilities | 611,790 | 488,992 |
| Shareholders' Deficit: | ||
| Preferred stock, $ 0.001 par value; 5,000,000 shares authorized | 0 | 0 |
| Common stock, $ 0.001 par value; 699,999,999 shares authorized; 695,251,000 and 541,000,000 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively. | 695,251 | 541,000 |
| Additional paid-in capital | 2,720,611 | 2,440,709 |
| Accumulated deficit | (3,901,937) | (3,210,737) |
| Total shareholders' deficit | (486,075) | (229,028) |
| Total liabilities and shareholders' deficit | $ 125,714 | $ 259,964 |
| Unaudited Condensed Consolidated Balance Sheets Parentheticals - $ / shares | Sep. 30, 2016 | Dec. 31, 2015 |
| Parentheticals | ||
| Preferred Stock, par value | $ 0.001 | $ 0.001 |
| Preferred Stock, shares authorized | 5,000,000 | 5,000,000 |
| Common Stock, par value | $ 0.001 | $ 0.001 |
| Common Stock, shares authorized | 699,999,999 | 699,999,999 |
| Common Stock, shares issued | 695,251,000 | 541,000,000 |
| Common Stock, shares outstanding | 695,251,000 | 541,000,000 |
| Unaudited Condensed Consolidated Statements of Operations - USD ($) | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2016 | Sep. 30, 2015 | Sep. 30, 2016 | Sep. 30, 2015 | |
| Revenue: | ||||
| Net Sales | $ 1,321 | $ 325 | $ 2,586 | $ 745 |
| Cost of Goods Sold | 394 | 166 | 750 | 264 |
| Gross Profit | 927 | 159 | 1,836 | 481 |
| Operating expenses: | ||||
| General and administrative | 26,065 | 25,727 | 101,786 | 56,991 |
| Salaries, wages, and related expenses | 89,911 | 71,323 | 267,638 | 193,489 |
| Selling expenses | 1,197 | 429 | 957 | 911 |
| Consulting fees | 2,000 | 55,467 | 148,750 | 83,800 |
| Legal and professional fees | 61,136 | 25,708 | 158,298 | 30,046 |
| Research and development | 0 | 0 | 5,990 | 0 |
| Total operating expenses | 180,309 | 178,654 | 683,419 | 365,237 |
| Loss from operations | (179,382) | (178,495) | (681,583) | (364,756) |
| Other income (expense): | ||||
| Interest expense | (3,366) | (1,301) | (9,617) | (4,140) |
| Total other income (expense) | (3,366) | (1,301) | (9,617) | (4,140) |
| Net loss from continuing operations | (182,748) | (179,796) | (691,200) | (368,896) |
| Net loss from discontinued operations | 0 | 0 | 0 | (8,722) |
| Net loss | $ (182,748) | $ (179,796) | $ (691,200) | $ (377,618) |
| Net loss per share - basic and diluted | $ 0 | $ 0 | $ 0 | $ 0 |
| Weighted average shares outstanding - basic and diluted | 684,275,390 | 467,869,565 | 644,158,474 | 440,619,048 |
| Unaudited Condensed Consolidated Statement of Changes in Shareholders' Deficit - 9 months ended Sep. 30, 2016 - USD ($) | Common Stock Shares | Common Stock Amount | Additional Paid-in Capital | Accumulated Deficit | Total |
| Balance at Jan. 01, 2016 | 541,000,000 | 541,000 | 2,440,709 | (3,210,737) | (229,028) |
| Stock issued for services on January 4, 2016 | 2,500,000 | 2,500 | 3,750 | 6,250 | |
| Stock issued for services on January 22, 2016 | 2,500,000 | 2,500 | 6,250 | 8,750 | |
| Stock issued for services on February 1, 2016 | 2,500,000 | 2,500 | 5,000 | 7,500 | |
| Stock issued on February 5, 2016 | 8,000,000 | 8,000 | 12,000 | 20,000 | |
| Stock issued for a license agreement on February 22, 2016 | 5,451,000 | 5,451 | 10,902 | 16,353 | |
| Stock issued on February 26, 2016 | 1,000,000 | 1,000 | 1,500 | 2,500 | |
| Stock issued for services on March 7, 2016 | 10,000,000 | 10,000 | 15,000 | 25,000 | |
| Stock issued on March 21, 2016 | 100,000,000 | 100,000 | 150,000 | 250,000 | |
| Stock issued on March 24, 2016 | 800,000 | 800 | 1,200 | 2,000 | |
| Stock issued on May 2, 2016 | 1,000,000 | 1,000 | 1,500 | 2,500 | |
| Stock issued for services on May 2, 2016 | 1,000,000 | 1,000 | 4,300 | 5,300 | |
| Stock issued on May 26, 2016 | 2,000,000 | 2,000 | 3,000 | 5,000 | |
| Stock issued for services on May 26, 2016 | 2,500,000 | 2,500 | 14,000 | 16,500 | |
| Stock issued for services on May 31, 2016 | 2,500,000 | 2,500 | 14,000 | 16,500 | |
| Stock issued on September 16, 2016 | 12,500,000 | 12,500 | 37,500 | 50,000 | |
| Net Loss | $ (691,200) | $ (691,200) | |||
| Balance at Sep. 30, 2016 | 695,251,000 | 695,251 | 2,720,611 | (3,901,937) | (486,075) |
| Unaudited Condensed Consolidated Statement of Cash Flows - USD ($) | 9 Months Ended | |
| Sep. 30, 2016 | Sep. 30, 2015 | |
| Cash flows from operating activities | ||
| Net loss | $ (691,200) | $ (377,618) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock based compensation to consultants | 85,800 | 126,300 |
| Shares issued for license agreement | 16,353 | 0 |
| Accrued interest, notes payable-related parties | 6,149 | 802 |
| Changes in operating assets and liabilities: | ||
| Inventory | (8,676) | (28,572) |
| Accounts receivable | 2,184 | 0 |
| Prepaid expenses and other current assets | 200,159 | 132,148 |
| Other assets | (16,368) | (15) |
| Accounts payable | 44,349 | (1,065) |
| Accrued expenses and other current liabilities | 73,444 | 3,387 |
| Cash used in operating activities-continuing operations | (287,806) | (144,633) |
| Cash provided (used) in operating activities-discontinued operations | 0 | 46,845 |
| Net cash used in operating activities | (287,806) | (97,788) |
| Cash flows from investing activities | ||
| Net cash used in investing activities | 0 | 0 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock | 332,000 | 105,000 |
| Proceeds from notes payable-related parties | 1,000 | 0 |
| Repayments of notes payable-related parties | (2,144) | (1,612) |
| Net cash provided by financing activities | 330,856 | 103,388 |
| Net increase in cash | 43,050 | 5,600 |
| Cash at beginning of period | 2,183 | 2,894 |
| Cash at end of period | 45,233 | 8,494 |
| Supplemental Cash Flow Information: | ||
| Cash paid for interest | 1,578 | 2,478 |
| Cash paid for income taxes | $ 800 | $ 800 |
| Organization and Business Description | 9 Months Ended |
| Sep. 30, 2016 | |
| Organization and Business Description | |
| Organization and Business Description | Note 1 Organization and Business Description Therapeutic Solutions International, Inc. (TSI or the Company) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation. Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) ones immune system. Activating ones immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting ones immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. Nutraceutical Division ® ® OmniBiome, Inc., TSI has experienced recurring losses over the past years which have resulted in accumulated deficits of approximately $3,902 thousand and a working capital deficit of approximately $515 thousand at September 30, 2016. These conditions raise uncertainty about the Companys ability to continue as a going concern. The Companys ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. |
| Summary of Significant Accounting Policies | 9 Months Ended |
| Sep. 30, 2016 | |
| Summary of Significant Accounting Policies: | |
| Summary of Significant Accounting Policies | Note 2 Summary of Significant Accounting Policies During the nine months ended September 30, 2016, there have been no changes to the Companys significant accounting policies as described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed with the SEC on October 31, 2016 and Form 10-K/A filed on January 25, 2017. . Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission (SEC) Regulation S-X, and should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2015, included in the Companys Annual Report on Form 10-K/A filed with the SEC on January 25, 2017. The accompanying unaudited condensed consolidated financial statements include the accounts of TSI and its subsidiary. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the balances and results for the interim period included herein. The results of operations for the three and nine months ended September 30, 2016 and 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated balance sheet at December 31, 2015, contained in the above referenced Form 10-K/A. Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Companys net loss. Net Loss Per Share Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding plus common stock equivalents. Common stock equivalents are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of September 30, 2016 and 2015, there were no common stock equivalents outstanding. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019 and will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entitys Ability to Continue as a Going Concern. The new standard requires management to assess, at each annual and interim reporting period, an entitys ability to continue as a going concern within one year after the date that the financial statements are issued and to provide related footnote disclosures. ASU 2014-15 will be effective for the Company for the year ending December 31, 2016. The adoption of this standard is not expected to have a material impact on the Companys financial position or results of operations. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for the Company in the first quarter of 2018 and allows for full retrospective or a modified retrospective adoption approach. The adoption of this standard is not expected to have a material impact on the Companys financial position or results of operations. |
| Restricted Cash | 9 Months Ended |
| Sep. 30, 2016 | |
| Restricted Cash: | |
| Restricted Cash | Note 3 Restricted Cash Other assets include a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2017, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011 . |
| Notes Payable Related Party | 9 Months Ended |
| Sep. 30, 2016 | |
| Notes Payable Related Party: | |
| Notes Payable Related Party | Note 4 Notes Payable-Related Party At September 30, 2016 and December 31, 2015, the Company has unsecured interest bearing demand notes outstanding to certain officers and directors amounting to $198,669 and $193,664, respectively. Interest accrued on these notes during the nine months ended September 30, 2016 and 2015 was $6,149 and $802, respectively. |
| Subsequent Events | 9 Months Ended |
| Sep. 30, 2016 | |
| Subsequent Events: | |
| Subsequent Events | Note 5 Subsequent Events On October 18, 2016, we issued 40,000,000 shares valued at $0.0045 to the officers and directors of the Company for services, and 5,000,000 shares valued at $0.0045 for consulting services. On November 29, 2016, we issued an eighteen month 8% Convertible Note to a Related Party for $75,000. On January 17, 2017, we issued 12,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Companys Private Placement by a related party. On March 2, 2017, we issued 12,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Companys Private Placement by a related party. |
| Accounting Policies (Policies) | 9 Months Ended |
| Sep. 30, 2016 | |
| Accounting Policies: | |
| Basis of Presentation | Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission (SEC) Regulation S-X, and should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2015, included in the Companys Annual Report on Form 10-K/A filed with the SEC on January 25, 2017. The accompanying unaudited condensed consolidated financial statements include the accounts of TSI and its subsidiary. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the balances and results for the interim period included herein. The results of operations for the three and nine months ended September 30, 2016 and 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated balance sheet at December 31, 2015, contained in the above referenced Form 10-K/A. |
| Use of Estimates | Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. |
| Comprehensive Loss | Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Companys net loss. |
| Net Loss Per Share | Net Loss Per Share Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding plus common stock equivalents. Common stock equivalents are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of September 30, 2016 and 2015, there were no common stock equivalents outstanding. |
| Recent Accounting Pronouncements | Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019 and will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entitys Ability to Continue as a Going Concern. The new standard requires management to assess, at each annual and interim reporting period, an entitys ability to continue as a going concern within one year after the date that the financial statements are issued and to provide related footnote disclosures. ASU 2014-15 will be effective for the Company for the year ending December 31, 2016. The adoption of this standard is not expected to have a material impact on the Companys financial position or results of operations. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for the Company in the first quarter of 2018 and allows for full retrospective or a modified retrospective adoption approach. The adoption of this standard is not expected to have a material impact on the Companys financial position or results of operations. |
| Restricted Cash (Details) | Sep. 30, 2016USD ($) |
| Restricted Cash Details | |
| Other non-current asset certificate of deposit | $ 10,000 |
| Annual interest rate | 0.60% |
| Notes Payable Related Party (Details) - USD ($) | Sep. 30, 2016 | Dec. 31, 2015 | Sep. 30, 2015 |
| Notes Payable Related Party Details | |||
| unsecured interest bearing demand notes outstanding | $ 198,669 | $ 193,664 | $ 0 |
| Interest accrued | $ 6,149 | $ 0 | $ 802 |
| Subsequent Events (Details) - USD ($) | Mar. 02, 2017 | Jan. 17, 2017 | Nov. 29, 2016 | Oct. 18, 2016 |
| Subsequent Events Details | ||||
| Issued shares of common stock for an investment in Private Placement per share | $ 0.004 | $ 0.004 | ||
| Issued shares of common stock for for an investment in Private Placement | 12,500,000 | 12,500,000 | ||
| Issued shares to the officers and directors for services | 40,000,000 | |||
| Issued shares to the officers and directors for services per share | $ 0.0045 | |||
| Issued shares for consulting services | 5,000,000 | |||
| Issued shares for consulting services per share | $ 0.0045 | |||
| Issued an eighteen month 8% Convertible Note to a Related Party value | $ 75,000 |
